KAYE RANDALL (CMO) sold 48.2% of their position (16.67K shares) of LONGBOARD PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $983.9K — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 10/16/2024ACC: 0000950170-24-115026
Officer· CMO
Since Mar 2022
-16.67K
Net shares
Net seller
$983.9K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
16.67K acquired · 33.33K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+16.67K
Price / share
$4.35
Trade value
$72.50K
% of position
93.0%
10/15/2024
17.92K→34.59K
Common Stock
Direct
Shares
−16.67K
Price / share
$59.03
Trade value
$983.94K
% of position
48.2%
10/15/2024
34.59K→17.92K
Total
Net shares
+0.00
Net value
-$911.43K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 10/15/2024 | M · Option Exercise | +16.67K | $4.35 | $72.50K | 93.0% | 17.92K | 34.59K |
| Common Stock Direct | 10/15/2024 | S · Sale | −16.67K | $59.03 | $983.94K | 48.2% | 34.59K | 17.92K |
| Total | +0.00 | -$911.43K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
16.67K shares
Shares
−16.67K
Strike price
4.35
Held after
96.30K
Exercisable
—
10/15/2024
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock16.67K shares | 10/15/2024 | M · Option Exercise | −16.67K | 4.35 | — | 96.30K |